Advertisement
U.S. markets closed

  • S&P 500

    4,604.37
    +18.78 (+0.41%)
     

  • Dow 30

    36,247.87
    +130.49 (+0.36%)
     

  • Nasdaq

    14,403.97
    +63.98 (+0.45%)
     

  • Russell 2000

    1,880.82
    +12.57 (+0.67%)
     

  • Crude Oil

    71.26
    +1.92 (+2.77%)
     

  • Gold

    2,020.80
    -25.60 (-1.25%)
     

  • Silver

    23.29
    -0.77 (-3.20%)
     

  • EUR/USD

    1.0764
    -0.0034 (-0.31%)
     

  • 10-Yr Bond

    4.2450
    +0.1160 (+2.81%)
     

  • GBP/USD

    1.2551
    -0.0043 (-0.34%)
     

  • USD/JPY

    144.8930
    +0.7020 (+0.49%)
     

  • Bitcoin USD

    44,319.46
    +840.43 (+1.93%)
     

  • CMC Crypto 200

    914.81
    +18.10 (+2.02%)
     

  • FTSE 100

    7,554.47
    +40.75 (+0.54%)
     

  • Nikkei 225

    32,307.86
    -550.45 (-1.68%)
     

EU agency backs GSK melanoma drug, wider use of Bayer's Nexavar

Reuters

LONDON, April 25 (Reuters) - European regulators said on Friday they had recommended approval of GlaxoSmithKline's melanoma drug Mekinist and also endorsed wider use of Bayer's Nexavar as a treatment for thyroid cancer.

Mekinist is one of several drugs being sold to Novartis under an asset swap deal.

Recommendations for marketing approval by the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.

(Reporting by Ben Hirschler; editing by Martinne Geller)

Advertisement